Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients

Transplant International

Volumn 25, Issue 6, 2012, Pages 680-686

  Sunder Plassmann, Gere ^a   Reinke, Petra ^b   Rath, Thomas ^c   Wiecek, Andrzej ^d   Nowicki, Michal ^e   Moore, Richard ^f   Lutz, Jens ^g   Gaggl, Martina ^a   Ferkl, Marek ^h  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Westpfalz Klinikum GmbH   (Germany)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e UNIVERSITY OF LODZ   (Poland)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h Teva Pharmaceuticals Europe   (United Kingdom)

Author keywords

generic immunosuppressant; kidney transplantation; mycophenolate mofetil; mycophenolic acid; pharmacokinetics

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

AREA UNDER THE CURVE; BOWENOID PAPULOSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LOWER RESPIRATORY TRACT INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREMOR; URINARY TRACT INFECTION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS; YOUNG ADULT;

EID: 84861186205     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01475.x     Document Type: Conference Paper

References (25)

1. Allison AC, Eugui EM,. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136: 5.
2. Allison AC, Eugui EM,. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85.
3. European Medicines Agency. European Public Assessment Report. Myfenax. Summary for the Public; 2008.
4. Opelz G, Döhler B,. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795.
5. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
6. Weimer R, Deisz S, Dietrich H, et al. Impact of maintenance immunosuppressive regimens-balance between graft protective suppression of immune functions and a near physiological immune response. Transpl Int 2011; 24: 596.
7. Srivatsan V, Dasgupta AK, Kale P, et al. Determination of mycophenolic acid in human plasma by high-performance liquid chromatography. J Chromatogr A 2004; 103: 259.
8. Fleming DH, Mathew BS, John GT, Chandy SJ, Manivannan J, Jeyaseelan V,. A six-hour extrapolated sampling strategy for monitoring mycophenolic acid in renal transplant patients in the Indian subcontinent. J Postgrad Med 2006; 52: 248.
9. Guerra G, Ciancio G, Gaynor JJ, et al. Randomized trial of immunosuppressive regimens in renal transplantation. J Am Soc Nephrol 2011; 22: 1758.
10. Klintmalm GB,. Immunosuppression, generic drugs and the FDA. Am J Transplant 2011; 11: 1765.
11. Alloway RR, Isaacs R, Lake K, et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 2003; 3: 1211.
12. van Gelder T, and ESOT Advisory Committee on Generic Substitution. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transplant Int 2011; 24: 1135.
13. Diarra DA, Riegersperger M, Saemann MD, Sunder-Plassmann G,. Maintenance immunosuppressive therapy and generic cyclosporine A use in adult renal transplantation: a single center analysis. Kidney Int Suppl 2010; 77 (Suppl 115): S8.
14. Vitko S, Ferkl M,. Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial. Kidney Int Suppl 2010; 77 (Suppl 115): S12.
15. Momper JD, Ridenour TA, Schonder KS, Shapiro R, Humar A, Venkataramanan R,. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant 2011; 11: 1861.
16. Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010; 5: 341.
17. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL,. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3: 534.
18. Staatz CE, Tett SE,. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46: 13.
19. Almeida S, Filipe A, Neves R, et al. Mycophenolate mofetil 500-mg tablet under fasting conditions: single-dose, randomized-sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjects. Clin Ther 2010; 32: 556.
20. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y,. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005; 78: 351.
21. Winnicki W, Weigel G, Sunder-Plassmann G, et al. An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid. Pharmacogenomics J 2010; 10: 70.
22. Lorenz M, Wolzt M, Weigel G, et al. Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. Am J Kidney Dis 2004; 43: 1098.
23. Levesque E, Benoit-Biancamano MO, Delage R, Couture F, Guillemette C,. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Pharmacogenomics 2008; 9: 869.
24. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T,. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305.
25. Ponticelli C, Colombo D, Novara M, Basilisco G, Group CS,. Gastrointestinal symptoms impair quality of life in Italian renal transplant recipients but are under-recognized by physicians. Transpl Int 2010; 23: 1126.